HOME EDITORIAL BOARD CONTACT US SUBSCRIPTION AUTHORS INDEX AUTHORS INSTRUCTIONS SUPPLEMENTARY DATA




   
 VOLUME 15 - NUMBER 1
/ January - March 2013

 
HIV-2 Susceptibility to Entry Inhibitors
Pedro Borrego and Nuno Taveira |Full Article in PDF|
Centre for Molecular Pathogenesis, Retrovirus and Associated Infections Unit (URIA-CPM), Faculty of Pharmacy, University of Lisbon, Lisbon, Portugal; Center of Interdisciplinary Investigation Egas Moniz (CiiEM), Institute of Health Sciences Egas Moniz, Caparica, Portugal
 
Abstract

Currently, there is a growing interest in using entry inhibitors to treat HIV-2-infected patients because, among the available drugs, few are fully active against HIV-2. Recent studies indicate that maraviroc and other experimental entry inhibitors, including new CCR5 and CXCR4 antagonists, inhibit primary isolates of HIV-2 as well as HIV-1 and may, therefore, expand the existing therapeutic armamentarium against HIV-2. There are, however, significant differences between the evolution of HIV-1 and HIV-2 envelope glycoproteins during infection that can lead to differences in the response to therapy with entry inhibitors over the course of the infection. Here, we review the available data on the susceptibility of HIV-2 to entry inhibitors in the context of the evolution of the sequence, structure, and function of envelope glycoproteins during infection.

 
Key words:
HIV-2. HIV envelope. Viral entry. Entry inhibitors. CCR5 antagonists. Fusion inhibitors.
 
Date: 23/09/2014
ISSN: 1698-6997
 
unsubscribe 

LOGIN 
Not a member?
REGISTER 

Editor's access. 

PERMANYER PUBLICATIONS
Mallorca, 310
08037 Barcelona - Spain
Phone: +34 93 207 59 20
Fax: +34 93 457 66 42
www.permanyer.com
LINKS:
Hepatology Reviews
Hepatology Reviews
 
Cancer & Chemotherapy Reviews
Cancer & Chemotherapy
Reviews
 
trends in transplantation
Trends in Transplantation


 
© 2014 Permanyer Publications
Made & Powered by IMMA PUIG
Mallorca, 310 - 08037 Barcelona, Spain. Tel.: +34 93 207 59 20 - Fax: +34 93 457 66 42